Table 4.
NIH-NCATS funded new therapeutic uses projects (2013–2018).
| Project/Study Title | Year | NCATS Program | Condition |
|---|---|---|---|
| The Efficacy and Safety of a Selective Estrogen Receptor Beta Agonist (LY500307) | 2013 | NIH-Industry Partnership | Schizophrenia |
| Fyn Inhibition by AZD0530 for Alzheimer’s Disease | 2013 | NIH-Industry Partnership | Alzheimer’s disease |
| Medication Development of a Novel Therapeutic for Smoking Cessation | 2013 | NIH-Industry Partnership | Cigarette smoking |
| A Novel Compound for Alcoholism Treatment: A Translational Strategy | 2013 | NIH-Industry Partnership | Alcoholism |
| Partnering to Treat an Orphan Disease: Duchenne Muscular Dystrophy | 2013 | NIH-Industry Partnership | Duchenne muscular dystrophy |
| Reuse of ZD4054 for Patients with Symptomatic Peripheral Artery Disease | 2013 | NIH-Industry Partnership | Peripheral artery disease |
| Therapeutic Strategy for Lymphangioleiomyomatosis | 2013 | NIH-Industry Partnership | Lymphangioleiomyomatosis |
| Therapeutic Strategy to Slow Progression of Calcific Aortic Valve Stenosis | 2013 | NIH-Industry Partnership | Calcific aortic valve stenosis |
| Translational Neuroscience Optimization of GlyT1 Inhibitor | 2013 | NIH-Industry Partnership | Schizophrenia |
| Anti-inflammatory Small Drug as Adjunctive Therapy to Improve Glucometabolic Variables in Obese, Insulin-Resistant Type 2 Diabetic Patients | 2015 | NIH-Industry Partnership | Insulin-resistant type 2 diabetes |
| Evaluation of AZD9291 in Glioblastoma Patients with Activated EGFR | 2015 | NIH-Industry Partnership | Glioblastoma |
| Evaluation of a Cathepsin S Inhibitor as a Potential Drug for Chagas Disease | 2015 | NIH-Industry Partnership | Chagas disease |
| Wee1 and HDAC Inhibition in Relapsed/Refractory AML | 2015 | NIH-Industry Partnership | Relapsed/refractory AML |
| Anti-Virulence Drug Repurposing Using Structural Systems Pharmacology | 2016 | Bench-to-Clinic | Bacterial virulence |
| CXCR2 Antagonism in the Immunometabolic Regulation of Type 2 Diabetes | 2016 | Bench-to-Clinic | Type 2 diabetes |
| Drug Repositioning in Diabetic Nephropathy | 2016 | Bench-to-Clinic | Diabetic nephropathy |
| Ketorolac and Related NSAIDs for Targeting Rho-Family GTPases in Ovarian Cancer | 2016 | Bench-to-Clinic | Ovarian cancer |
| Network-Driven Drug Repurposing Approaches to Treat Coronary Artery Disease | 2016 | Bench-to-Clinic | Coronary artery disease |
| Pre-Clinical Evaluation of a Neutrophil Elastase Inhibitor for the Treatment of Inflammatory Bowel Disease | 2016 | Bench-to-Clinic | Inflammatory bowel disease |
| Quantum Model Repurposing of Cethromycin for Liver Stage Malaria | 2016 | Bench-to-Clinic | Liver-stage malaria |
| Repurposing Lesogaberan for the Treatment of Type 1 Diabetes | 2016 | Bench-to-Clinic | Type 1 diabetes |
| Repurposing Misoprostol for Clostridium Difficile Colitis as Identified by PheWAS | 2016 | Bench-to-Clinic | Clostridium difficile colitis |
| Repurposing Pyronaridine as a Treatment for the Ebola Virus | 2016 | Bench-to-Clinic | Ebola virus |
| Therapeutic Repurposing of Benserazide for Colon Cancer | 2016 | Bench-to-Clinic | Colon cancer |
| Computational Repurposing of Chemotherapies for Pulmonary Hypertension | 2017 | Bench-to-Clinic | Pulmonary hypertension |
| Pre-Clinical Evaluation of Vorinostat in Alopecia Areata | 2017 | Bench-to-Clinic | Alopecia areata |
| Pre-Clinical Testing of a Novel Therapeutic for Nonalcoholic Steatohepatitis | 2017 | Bench-to-Clinic | Nonalcoholic steatohepatitis |
| Repurposing Pyronaridine as a Treatment for Chagas Disease | 2017 | Bench-to-Clinic | Chagas disease |
| Single-Cell-Driven Drug Repositioning Approaches to Target Inflammation in Atherosclerosis | 2017 | Bench-to-Clinic | Atherosclerosis |
| Impact of SAR152954 on Prenatal Alcohol Exposure-Induced Neurobehavioral Deficits | 2017 | Bench-to-Clinic | Neurobehavioral deficits |
| An Endoplasmic Reticulum Calcium Stabilizer for the Treatment of Wolfram Syndrome | 2017 | Bench-to-Clinic | Wolfram syndrome |
| Utilization of Phenotypic Precision Medicine to Identify Optimal Drug Combinations for the Treatment of Hepatocellular Carcinoma | 2017 | Bench-to-Clinic | Hepatocellular carcinoma |
| Targeting Glucose Metabolism for the Treatment of Hepatocellular Carcinoma | 2017 | Bench-to-Clinic | Hepatocellular carcinoma |
| Application of a Repurposed FDA Approved Drug as a Local Osteogenic Agent | 2017 | Bench-to-Clinic | To induce local osteogenesis |
| Repurposing Misoprostol to Prevent Recurrence of Clostridium Difficile Infection | 2018 | Bench-to-Clinic | Recurrent Clostridium difficile |
| AZD9668: A First in Class Disease Modifying Therapy to Treat Alpha-1 Antitrypsin Deficiency, a Genetically Linked Orphan Disease | 2018 | NIH-Industry Partnership | Alpha-1 antitrypsin deficiency |
| AZD9668 and Neutrophil Elastase Inhibition to Prevent Graft-versus-Host Disease | 2018 | NIH-Industry Partnership | Graft-versus-host disease |
| Use of the Src Family Kinase Inhibitor Saracatinib in the Treatment of Pulmonary Fibrosis | 2018 | NIH-Industry Partnership | Pulmonary fibrosis |